Fig. 5: STUB1 inactivation enhances IFNγ signaling and increases anti-PD-1 response in heterogeneous tumors with wildtype cells, but not in homogenous STUB1-deficient tumors. | Nature Communications

Fig. 5: STUB1 inactivation enhances IFNγ signaling and increases anti-PD-1 response in heterogeneous tumors with wildtype cells, but not in homogenous STUB1-deficient tumors.

From: Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling

Fig. 5: STUB1 inactivation enhances IFNγ signaling and increases anti-PD-1 response in heterogeneous tumors with wildtype cells, but not in homogenous STUB1-deficient tumors.

a Immunohistochemistry images of either sgCtrl or sgStub1-expressing B16F10-dOVA tumors in vivo. Tumor samples were stained for PD-L1. b Quantification using H-score of PD-L1-positive tumor cells in tumor samples depicted in a. c Schematic depiction of the in vivo competition assay modeling anti-PD-1 response with B16F10-dOVA cells expressing either sgCtrl or sgStub1, which were differentially labeled with EGFP and mCherry, respectively. d Flow cytometry plots from each group of the in vivo experiment outlined in c NSG, Isotype control-treated (αISO), anti-PD-1-treated (αPD-1). Number in quadrants indicates % of parent population. e Quantification of in vivo competition assay outlined in c. Ratios of mCherry vs. EGFP were normalized to the NSG condition. Mean ± SD in b, **p = 0.003, unpaired two-tailed t-test, n = 7 for sgCtrl and n = 6 for sgStub1. Mean ± SD in e, ***p = 0.0002, **p = 0.0073, n.s. p = 0.2985, ordinary one-way ANOVA with Tukey post hoc testing for n = 10 in NSG and αISO and n = 9 in αPD-1.

Back to article page